SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Emmaus Life Sciences, Inc. – ‘10-K’ for 9/30/15 – ‘R7’

On:  Tuesday, 1/5/16, at 5:13pm ET   ·   For:  9/30/15   ·   Accession #:  1615774-16-3804   ·   File #:  1-35527

Previous ‘10-K’:  ‘10-K/A’ on 1/23/15 for 9/30/14   ·   Next:  ‘10-K’ on 12/22/16 for 9/30/16   ·   Latest:  ‘10-K’ on 3/31/23 for 12/31/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/05/16  Emmaus Life Sciences, Inc.        10-K        9/30/15   77:6.5M                                   S2 Filings LLC/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    869K 
 2: EX-3.1.3    Articles of Incorporation/Organization or Bylaws    HTML     26K 
 3: EX-10.25    Material Contract                                   HTML     72K 
 4: EX-10.26    Material Contract                                   HTML     29K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     21K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     26K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     22K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     22K 
16: R1          Document and Entity Information                     HTML     50K 
17: R2          Consolidated Balance Sheets                         HTML    103K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     40K 
19: R4          Consolidated Statements of Operations               HTML     84K 
20: R5          Consolidated Statements of Changes in               HTML     58K 
                Stockholders' Deficit                                            
21: R6          Consolidated Statements of Cash Flows               HTML    112K 
22: R7          Nature of Operations                                HTML     39K 
23: R8          Summary of Significant Accounting Policies          HTML     84K 
24: R9          Discontinued Operations                             HTML     45K 
25: R10         Convertible Debt and Equity Financings              HTML     52K 
26: R11         Derivative Liabilities                              HTML     38K 
27: R12         Stockholders' Deficit                               HTML    121K 
28: R13         Income Taxes                                        HTML     46K 
29: R14         Related Party Transactions                          HTML     66K 
30: R15         Loss Per Share                                      HTML     41K 
31: R16         Commitments and Contingent Liabilities              HTML     50K 
32: R17         Significant Customers                               HTML     26K 
33: R18         Subsequent Events                                   HTML     61K 
34: R19         Summary of Significant Accounting Policies          HTML    127K 
                (Policies)                                                       
35: R20         Summary of Significant Accounting Policies          HTML     51K 
                (Tables)                                                         
36: R21         Discontinued Operations (Tables)                    HTML     43K 
37: R22         Convertible Debt and Equity Financings (Tables)     HTML     41K 
38: R23         Derivative Liabilities (Tables)                     HTML     34K 
39: R24         Stockholders' Deficit (Tables)                      HTML    101K 
40: R25         Income Taxes (Tables)                               HTML     44K 
41: R26         Loss Per Share (Tables)                             HTML     38K 
42: R27         Commitments and Contingent Liabilities (Tables)     HTML     35K 
43: R28         Subsequent Events (Tables)                          HTML     57K 
44: R29         Nature of Operations (Details Narrative)            HTML     48K 
45: R30         Summary of Significant Accounting Policies          HTML     30K 
                (Details)                                                        
46: R31         Summary of Significant Accounting Policies          HTML     34K 
                (Details 1)                                                      
47: R32         Summary of Significant Accounting Policies          HTML     61K 
                (Details Narrative)                                              
48: R33         Discontinued Operations (Details)                   HTML     41K 
49: R34         Discontinued Operations (Details 1)                 HTML     37K 
50: R35         Convertible Debt and Equity Financings (Details)    HTML     71K 
51: R36         Convertible Debt and Equity Financings (Details     HTML    110K 
                Narrative)                                                       
52: R37         Derivative Liabilities (Details)                    HTML     30K 
53: R38         Derivative Liabilities (Details Narrative)          HTML     58K 
54: R39         Stockholders' Deficit (Details)                     HTML     31K 
55: R40         Stockholders' Deficit (Details 1)                   HTML     43K 
56: R41         Stockholders' Deficit (Details 2)                   HTML     94K 
57: R42         Stockholders' Deficit (Details 3)                   HTML     44K 
58: R43         Stockholders' Deficit (Details 4)                   HTML     56K 
59: R44         Stockholders' Deficit (Details Narrative)           HTML     69K 
60: R45         Stockholders' Deficit (Details Narrative 1)         HTML    136K 
61: R46         Stockholders' Deficit (Details Narrative 2)         HTML     44K 
62: R47         Income Taxes (Details)                              HTML     39K 
63: R48         Income Taxes (Details 1)                            HTML     43K 
64: R49         Income Taxes (Details Narrative)                    HTML     27K 
65: R50         Related Party Transactions (Details Narrative)      HTML    171K 
66: R51         Related Party Transactions (Details Narrative 1)    HTML    198K 
67: R52         Loss Per Share (Details)                            HTML     54K 
68: R53         Commitments and Contingent Liabilities (Details)    HTML     57K 
69: R54         Commitments and Contingent Liabilities (Details     HTML     53K 
                Narrative)                                                       
70: R55         Significant Customers (Details Narrative)           HTML     31K 
71: R56         Subsequent Events (Details)                         HTML     40K 
72: R57         Subsequent Events (Details 1)                       HTML     38K 
73: R58         Subsequent Events (Details 2)                       HTML     37K 
74: R59         Subsequent Events (Details Narrative)               HTML     60K 
76: XML         IDEA XML File -- Filing Summary                      XML    131K 
75: EXCEL       IDEA Workbook of Financial Reports                  XLSX     89K 
10: EX-101.INS  XBRL Instance -- cnso-20150930                       XML   1.83M 
12: EX-101.CAL  XBRL Calculations -- cnso-20150930_cal               XML    157K 
13: EX-101.DEF  XBRL Definitions -- cnso-20150930_def                XML    752K 
14: EX-101.LAB  XBRL Labels -- cnso-20150930_lab                     XML   1.02M 
15: EX-101.PRE  XBRL Presentations -- cnso-20150930_pre              XML    963K 
11: EX-101.SCH  XBRL Schema -- cnso-20150930                         XSD    163K 
77: ZIP         XBRL Zipped Folder -- 0001615774-16-003804-xbrl      Zip    152K 


‘R7’   —   Nature of Operations


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.3.1.900
NATURE OF OPERATIONS
12 Months Ended
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS

1. NATURE OF OPERATIONS

 

Organization and Nature of Operations

 

At the meeting of shareholders of CNS Response, Inc. held on October 28, 2015, the shareholders approved a proposal to change the Company’s name to MYnd Analytics, Inc. The Company’s charter was officially amended on November 2, 2015.

MYnd Analytics, Inc. (“MYnd,” “CNS,” “we,” “us,” “our,” or the “Company”), formerly known as CNS Response Inc., was incorporated in Delaware on March 20, 1987, under the name Age Research, Inc.  Prior to January 16, 2007, the Company (then called Strativation, Inc.) was a “shell company” with nominal assets and our sole business was to identify, evaluate and investigate various companies to acquire or with which to merge.  On January 16, 2007, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with CNS Response, Inc., a California corporation formed on January 11, 2000 (“CNS California”), and CNS Merger Corporation, a California corporation and the Company’s wholly-owned subsidiary (“MergerCo”) pursuant to which the Company agreed to acquire CNS California in a merger transaction wherein MergerCo would merge with and into CNS California, with CNS California being the surviving corporation (the “Merger”). On March 7, 2007, the Merger closed, CNS California became a wholly-owned subsidiary of the Company, and on the same date the corporate name was changed from Strativation, Inc. to CNS Response, Inc. At the annual meeting held on October 28, 2015, shareholders approved a change in our name from CNS Response, Inc. to MYnd Analytics, Inc. On November 2, 2015, the Company filed an amendment to its Articles of Incorporation which, among other things, effected the name change to MYnd Analytics, Inc.

 

The Company is a cloud-based predictive analytics company that provides objective clinical decision support to mental healthcare providers for the treatment of behavioral disorders, including depression, anxiety, bipolar disorder and post-traumatic stress disorder (“PTSD”). The Company uses its proprietary neurometric platform, PEER Online, to generate Psychiatric EEG Evaluation Registry (“PEER”) Reports to predict the likelihood of response by an individual to certain medications for the treatment of behavioral disorders. In April 2013, the Company commenced a reimbursed clinical trial at Walter Reed National Military Medical Center (“Walter Reed”) and Fort Belvoir Community Hospital (“Fort Belvoir”) (collectively, the “Walter Reed PEER Trial”) using its neurometric platform to provide PEER Reports to military psychiatrists treating patients primarily for depression with various comorbidities, including PTSD and mild traumatic brain injury (“mTBI”). In April 2014, based on an interim analysis of less than 10% of the planned clinical trial enrollees, statistically significant results were achieved for ten of twelve endpoints of the Walter Reed PEER Trial. In May 2014, following the interim analysis, the Walter Reed Institutional Review Board (the “Walter Reed IRB”) suspended enrollment of new patients in order to conduct an internal review. Our management expected enrollment of the Walter Reed PEER Trial to recommence in 2015: however, due to limited action on the part of the Walter Reed IRB, or Walter Reed Leadership, and no formal communication or due-process, we now believe that the Walter Reed PEER Trial is unlikely to re-start in the foreseeable future. Consequently, management intends to conduct a clinical trial focused on Southern California (the “SoCal Trial”) and using substantially the same protocol as had been approved by the Walter Reed IRB. Our management believes the SoCal Trial will provide additional information to demonstrate the clinical and economic utility of our neurometric platform. We are also focusing our marketing efforts on Southern California to boost our commercialization of the PEER Online platform and its PEER Reports.

 

The Company acquired the Neuro-Therapy Clinic, Inc. (“NTC”) on January 15, 2008, to provide behavioral health care services.  NTC’s operations were discontinued effective September 30, 2012. See Note 3. Discontinued Operations.

  

Going Concern Uncertainty

 

The accompanying condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), which contemplate continuation of the Company as a going concern. The Company has a limited operating history and its operations are subject to certain problems, expenses, difficulties, delays, complications, risks and uncertainties frequently encountered in the operation of a business with a limited operating history. These risks include the ability to obtain adequate financing on a timely basis, if at all, the failure to develop or supply technology or services to meet the demands of the marketplace, the failure to attract and retain qualified personnel, competition within the industry, government regulation and the general strength of regional and national economies.

 

The Company’s continued operating losses and limited capital raise substantial doubt about its ability to continue as a going concern. The Company has limited cash resources for its operations and will need to raise additional funds to meet its obligations as they become due. As of September 30, 2015, we had an accumulated deficit of $62,592,900. For the year ended September 30, 2015, we had a net loss from operations of $3,379,400 and net cash used in operating activities of $2,114,800.

 

To date, the Company has financed its cash requirements primarily from debt and equity financings.  The Company will need to raise additional funds immediately to continue its operations and needs to raise substantial additional funds before the Company can increase demand for its PEER Online services. Until it can generate a sufficient amount of revenues to finance its cash requirements, which it may never do, the Company must continue to finance future cash needs primarily through public or private equity offerings, debt financings, borrowings or strategic collaborations. The Company’s liquidity and capital requirements depend on several factors, including the rate of market acceptance of its services, the future profitability of the Company, the rate of growth of the Company’s business and other factors described elsewhere in this Annual Report on Form 10-K.  The Company continues to explore additional sources of capital, but there is substantial doubt as to whether any financing arrangement will be available in amounts and on terms acceptable to the Company to permit it to continue operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

  

Between October 4, 2013 and September 23, 2015, the Company issued an aggregate of 6,940,000 shares of its Common Stock, at a price of $0.25 per share, in private placements to an aggregate of 20 accredited investors. The gross proceeds to the Company were $1,735,000, net of $44,000 in placement agent fees for net proceeds to the Company of $1,691,000. Furthermore between September 22, 2014, and September 24, 2015, the Company issued secured convertible debt in the aggregate principal amount of $3,000,000. During the 2015 fiscal year the aggregate gross proceeds to the Company were $1,350,000 from the debt offering. 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:1/5/16
11/2/15
10/28/158-K,  DEF 14A
For Period end:9/30/158-K,  CORRESP,  NT 10-K,  PRER14A
9/24/153,  4,  8-K
9/23/15
9/22/148-K
10/4/138-K
9/30/1210-K,  10-K/A,  NT 10-K
1/15/083
3/7/073,  8-K
1/16/078-K
1/11/00
 List all Filings 
Top
Filing Submission 0001615774-16-003804   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Apr. 28, 12:21:05.1am ET